PRDS / All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy

Pardes Biosciences Inc.'s PRDS, -0.54% stock was up 12.4% in premarket trades Monday after the clinical-stage biopharmaceutical company said it agreed more_horizontal

Pardes Biosciences, Inc. (PRDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m more_horizontal

Pardes Biosciences Seeking Strategic Alternatives. Pardes' Pipeline is depleted. more_horizontal

CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing P more_horizontal

Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal

Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal

Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal

The FDA has signed off Pardes Biosciences Inc's PRDS Investigational New Drug (IND) application for PBI-0451 for COVID-19. Get the Inside Access Tr more_horizontal